Dizal Pharmaceutical Announces that Its Report on Phase I Clinical Studies of DZD9008 in NSCLC with EGFR Exon20 Insertion Mutations Has Been Selected for Oral Presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

Dizal Pharmaceutical, a clinical-stage pharmaceutical company dedicated to discovery, development and commercialization of innovative medicines for the treatment of cancer and immunological diseases, today announces that the preliminary safety and efficacy results from phase I studies of DZD9008 in NSCLC patients with EGFR Exon20 insertion mutations will be presented in oral session at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place on June 4-8, 2021. Details of the oral presentation are as follows: Title: Preliminary safety and efficacy results from phase I studies of DZD9008 in NSCLC patients with EGFR Exon20 insertion mutations Abstract #: 9008Session: Lung Cancer—Non-Small Cell Metastatic Time：6/4/2021, 1:00 PM-4:00 PM EDT Author: James Chih-Hsin Yang, Mengzhao Wang, Paul Mitchell, Jian Fang, Weiqi Nian, Chao-Hua Chiu, Jianying Zhou, Yanqiu Zhao, Wu-Chou Su, D. R. Camidge, Tsung-Ying Yang, Viola W. Zhu, Michael Millward, Yun Fan, Wen Tsung Huang, Ying Cheng, Liyan Jiang, Li Zheng, Xiuhui Ye, Pasi A. Janne

The release as fetched from its publisher. dizalpharma.com ↗